ImmunityBio, Inc. IBRX

IBRX Company Overview

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company operates within the biotechnology and biopharmaceutical industries, with a core emphasis on leveraging the immune system to treat malignancies and prevent or control infectious threats. Its primary value driver is the development and commercialization of immune-enhancing biologics designed to activate both innate and adaptive immune responses.

The company’s lead product is Anktiva® (nogapendekin alfa inbakicept), an interleukin-15 (IL‑15) superagonist complex that has been approved in the United States for certain patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ. ImmunityBio’s strategy centers on combination immunotherapy and durable immune memory, positioning the company distinctively relative to checkpoint inhibitor–focused peers. ImmunityBio was formed through the merger of NantKwest, Inc. and ImmunityBio in 2021, consolidating oncology-focused immunotherapy assets originally developed within the NantWorks ecosystem founded by Patrick Soon-Shiong.